Noninfectious uveitis (NIU) comprises a heterogeneous group of recurrent or chronic sight-threatening intraocular inflammations that eventually lead to permanent visual impairment or blindness in up to 19% of patients. Noninfectious uveitis affects more than 1 of every 1000 individuals and usually demands treatment for decades, the clinical and economic impact of NIU is enormous.  

NIU is well acknowledged as an immune-mediated disease. This is based upon (genetic) association with numerous immune-related molecules, the frequent occurrence of uveitis in relation to systemic inflammatory conditions, and the beneficial response to immunosuppressive therapy. Despite our growing understanding that susceptibility to NIU is in part genetic, and epigenetic modulation contributes to various inflammatory pathways and an altered composition of leukocyte subsets to noninfectious uveitis.  

A Disease-Associated MicroRNA Cluster Links Inflammatory Pathways and an Altered Composition of Leukocyte Subsets to Noninfectious Uveitis

Fleurieke H. Verhagen,1–3 Cornelis P. J. Bekker,3 Marzia Rossato,3 Sanne Hiddingh,1,3 Lieuwe de Vries,4 Abhinandan Devaprasad,3 Aridaman Pandit,3 Jeannette Ossewaarde-van Norel,2 Ninette ten Dam,2 Maartje C. A. Moret-Pot,2 Saskia M. Imhof,2 Joke H. de Boer,1,2 Timothy R. D. J. Radstake,1,3,5 and Jonas J. W. Kuiper1–3

1Ophthalmal-Immunology Unit, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2Department of Ophthalmology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
3Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
4Department of Ophthalmology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
5Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Correspondence: Fleurieke H. Verhagen, Department of Ophthalmal-Immunology, University Medical Center Utrecht, Room B05 2.30, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; F.H.Verhagen@umcutrecht.nl.

Purpose. The cause of noninfectious uveitis (NIU) is poorly understood but is considered to be mediated by a complex interplay between genetic, environmental, and—relatively unexplored—epigenetic factors. MicroRNAs (miRNAs) are noncoding small RNAs that are important epigenetic regulators implicated in pathologic signaing. Therefore, we mapped the circulating miRNA-ome of NIU patients and studied miRNA perturbations within the broader context of the immune system.

Methods. We designed a strategy to robustly identify changes in the miRNA profiles of two independent cohorts totaling 54 untreated patients with active and eye-restricted disease and 26 age-matched controls. High-resolution miRNA-ome data were obtained by TaqMan OpenArray technology and subsequent RT-qPCR. Flow cytometry data, and proteomic data spanning the cellular immune system, were used to map the uveitis-miRNA signature to changes in the composition of specific leukocyte subsets in blood.

Results. Using stringent selection criteria, we identified and independently validated an miRNA cluster that is associated with NIU. Pathway enrichment analysis for genes targeted by this cluster revealed significant enrichment for the PI3K/Akt, MAPK, FOXO, and VEGF signaling pathways, and photoreceptor development. In addition, unsupervised multidomain analyses linked the presence of the uveitis-associated miRNA cluster to a different composition of leukocyte subsets, more specifically, CD16+/CD11c-/HLA-DR+ cells.

Conclusions. Together, this study identified a unique miRNA cluster associated with NIU that was related to changes in leukocyte subsets demonstrating systemic changes in epigenetic regulation underlying NIU.

Keywords: microRNA, uveitis, epigenetics, Birdshot, intraocular inflammation
novel therapeutic targets for treatment. But despite their potential, miRNA profiling studies are particularly prone to low reproducibility and have hitherto delivered little clinical utility. This can in part be attributed to experimental design (e.g., validation via independent cohorts). In addition, functional understanding of the implications of changes in miRNA levels is usually confined to knockdown and/or overexpression studies of only one or a few targets in single (nonprimary) cell types.

To overcome the aforementioned limitations, we designed a strategy to robustly identify differences in the miRNA profile of the serum of patients with NIU.

**Materials and Methods**

**Patients and Patient Material**

We collected blood from a total of 54 adult patients with one of three archetypical types of NIU: HLA-B27–associated acute anterior uveitis (AU), idiopathic intermediate uveitis (IU), or Birdshot uveitis (BU). Patients were seen at the outpatient patient clinic of the Department of Ophthalmology of the University Medical Center Utrecht between July 2014 and December 2016. Patients were divided between a discovery cohort (AU: n = 9, IU: n = 9, BU: n = 10) and a replication cohort (AU: n = 10, IU: n = 6, BU: n = 10). All patients had active uveitis (new onset or relapse) at the time of sampling. None of the patients had a related systemic autoimmune or autoimmune disease, nor did they receive systemic immunomodulatory treatment in the last 5 months, other than a low dose of oral prednisolone (≤10 mg, n = 1).

Uveitis was classified and graded in accordance with the Standardization of Uveitis Nomenclature (SUN) classification. For detailed information on the clinical workup see Supplementary Methods. Twenty-six age- and sex-matched anonymous blood donors with no history of ocular inflammatory disease (UCM Utrecht) served as unaffected controls.

This study was conducted in compliance with the Declaration of Helsinki. Ethical approval was requested and obtained from the Medical Ethical Research Committee in Utrecht and all patients signed written informed consent before participation.

**MicroRNA Profiling: OpenArray**

Total RNA was extracted from 200 μL serum by using Exiqon’s mirCURY RNA Isolation Kit for biofluids (Exiqon, Vedbaek, Denmark), according to the manufacturer’s instructions. RNA extraction was performed for all serum samples on the same day and the order of samples randomized according to previous recommendations. Because there are currently no universally applicable endogenous serum control miRNAs and to facilitate reproducibility (standardized controls), we used nonhuman miRNA (ath-MiR-159a) as a spike-in control for normalization. More details on RNA isolation are provided in the Supplementary Methods.

We screened for 758 miRNAs in the serum of the discovery cohort by using the TaqMan OpenArray platform (Thermo Fisher, Waltham, MA, USA) according to the manufacturer’s instructions (see also Supplementary Methods). The resulting expression levels, given in cycle threshold (Crt) values of all miRNAs, were normalized by subtraction of the mean Crt value of the spike-in, resulting in a deltaCrt (ΔCrt = Crt mean target – Crt mean ath-MiR-159a). Differences in miRNA expression levels between patients and controls were assessed by comparing these ΔCrt values of patients to healthy controls, using the comparative threshold cycle method. In short, expression levels are presented as the fold change (FC = 2 – ΔΔCrt, where ΔΔCrt = ΔCrt patient – ΔCrt reference) as compared to the healthy control that represented the median of the spike-in and was set to 1 (FC). miRNAs were selected for validation if they were well expressed (mean Crt < 27, amplification score of >1.24), in >90% of all samples, with FC of ≥2 or <0.5, and a P value of <0.05.

**Validation of miRNAs: TaqMan Single RT-qPCR**

We performed TaqMan single quantitative reverse transcription–PCR (RT-qPCR) (see also Supplementary Methods) for 10 miRNAs that passed the selection criteria, on the same samples from the discovery cohort. The Crt values from the TaqMan assay were compared with the Crt values from the OpenArray platform. miRNAs were considered technically validated when Spearman’s ρ > 0.5 and P < 0.05. All validated miRNAs were tested in a second, independent replication cohort (n = 36) for biological validation.

**Statistical Approaches**

The OpenArray analysis was done by using the Thermo Fisher Cloud software, which follows an independent samples t-test to compare ΔΔCrt data with a P value threshold below 0.05 (two-tailed). To facilitate discovery of potentially meaningful mediators, we applied correction for multiple testing only to the combined data set (discovery + replication cohort), which was obtained after a more robust three-staged strategy of discovery, validation, and replication using independent technologies and cohorts. In the combined cohorts, nonparametric tests (Mann-Whitney U test, Kruskal-Wallis with post hoc Dunn’s with adjusted P values, Spearman’s ρ) were used to compare groups or test for correlations. Selected individual miRNAs were subjected to receiver operating characteristic (ROC) curves using the FC values.

Details on the association between miRNAs (ΔΔCrt) and clinical characteristics are described in Supplementary Methods. To correct for multiple testing, a P value of <0.0055 (0.05/9 clinical parameters) was considered significant.

The FC values (or singular value decomposition imputed values, max 10%) for miRNAs that met the amplification and expression criteria were subjected to unsupervised hierarchical clustering (Euclidian distance, Ward’s linkage method). Clustering was performed with ClustVis or MetaboAnalyst. Statistical analyses were performed in SPSS version 21.0 (SPSS, Inc., Chicago, IL, USA), GraphPad Prism (GraphPad, La Jolla, CA, USA), MetaboAnalyst Server v3.0, and R v3.3.2.

**Target Analysis**

Predicted and reported mRNA targets of the validated miRNAs were mapped by using miRGate and MirTargetLink. Pathway enrichment analysis was performed for Gene Ontology (GO) biological processes, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, and Pathway Ontology (PW) pathways on all gene targets that were targeted by at least two miRNAs, using ToppGene Suite (BMI CHMC, Cincinnati, OH, USA). To visualize shared pathways, unscaled false discovery rate (FDR)-corrected P values for pathways related to inflammation and eye biology were outlined in a heatmap generated by Clustvis software.

**Leukocyte Cell Subset MicroRNA and Proteome Analyses**

Global miRNA expression data for nine primary leukocyte populations were derived from four noncoding RNA micro-
specific protein expression data. For detailed information see leukocyte subsets (162 samples) were used to obtain the cell-spectrometry–based proteomics data for the nine primary populations by using the significance analysis of microarrays numbers of samples, we explored the abundance of cell CD303 proteins. Since we investigated groups with unequal CD19), CD14, CD1c, HLA-DR, CD123, CD11c, CD141, and were clustered by the expression of lineage (CD3/CD56/ supervised classification model to highlight stratifying clusters which results in a so-called tree. This is followed by a In short, Citrus applies an unsupervised clustering algorithm to for each sample with a 1% minimum cluster size to reduce tary Fig. S1) viable single cells exported from Flow Jo Software we performed unsupervised hierarchical clustering by using Citrus on 50,000 random events from pregated (Supplemen-We devised a three-staged strategy with stringent selection criteria to identify differently expressed miRNAs in serum of NIU patients (Supplementary Fig. S2). The demographic data of the NIU patients and controls from the discovery cohort and the replication cohort are shown in the Table. First, we screened for 758 circulating miRNAs in 28 patients and 16 healthy controls (discovery cohort) by using a high-throughput real-time PCR platform (OpenArray). A total of 102 miRNAs passed quality control (Supplementary Table S3). We could distinguish patients from controls from the overall miRNA profile (Fig. 1), which exhibited mostly increased levels for most detected miRNAs (Supplementary Fig. S3). To aid in the elimination of background variation and improve reproducibility of our findings, we maintained a stringent 2-fold change cutoff and P < 0.05 for significance. This approach yielded six miRNAs (miR-140-5p, miR-191-5p, miR-223-3p, miR-223-5p, miR-195a-5p, and miR-29a-3p) and a small nuclear RNA (U6 snRNA) that were upregulated in one or more patient groups compared to healthy controls (Supplementary Fig. S5; Supplementary Table S4). Between the uveitis groups, three miRNAs (miR-127-5p, miR-375, miR-409-3p) were differentially expressed (Supplementary Fig. S3; Supplementary Table S4), resulting in a total of 10 miRNAs that were selected for replication.

High-throughput miRNA profiling technologies are inherently prone to detect certain miRNAs over others. We performed several investigations that showed no apparent detection bias and thus we consider the detected miRNA profile a genuine representative sample of the blood-borne miRNA-ome of NIU (see Supplementary Methods; Supplementary Fig. S4).

Replication of Seven Serum miRNAs in an Independent Cohort

We next technically validated the miRNAs from the discovery cohort by using RT-qPCR. The expression levels for 9/10 miRNAs demonstrated strong correlation (r = 0.55–0.97; all P ≤ 0.0001) between these technologies and were thus considered technically validated (Fig. 2; Supplementary Table S4). Next, we investigated the levels of these nine miRNAs in an independent cohort of 26 patients and 10 controls (Table). Biological replication was achieved for six miRNAs (miR-140-5p, miR-191-5p, miR-223-3p, miR-223-5p, miR-195a-5p, and miR-491-5p) and U6 snRNA in at least one of the uveitis disease groups versus healthy controls (Fig. 2; Supplementary Table S4). All were significantly more highly expressed in uveitis patients than the controls (Fig. 2D).

Since an increase in the levels of the replicated miRNAs was observed for all uveitis subtypes, we combined the TaqMan RT-qPCR data from both cohorts to investigate the discriminative power of the uveitis-associated cluster. The analysis of the area

### Table. Characteristics of the Discovery and Replication Cohorts Investigated in This Study

<table>
<thead>
<tr>
<th></th>
<th>AU</th>
<th>IU</th>
<th>BU</th>
<th>HC</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discovery Cohort</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>9</td>
<td>9</td>
<td>10</td>
<td>16</td>
<td>N/A</td>
</tr>
<tr>
<td>Male/female</td>
<td>3/6</td>
<td>2/7</td>
<td>4/6</td>
<td>6/10</td>
<td>0.90*</td>
</tr>
<tr>
<td>Age, mean ± SD, y</td>
<td>47.7 ± 17.0</td>
<td>39.3 ± 14.0</td>
<td>52.9 ± 13.2</td>
<td>41.4 ± 9.8</td>
<td>0.09**</td>
</tr>
<tr>
<td>Disease duration, median (range), y</td>
<td>5.8 (0.1–39.3)</td>
<td>3.7 (0.2–20.0)</td>
<td>1.3 (0.2–15.1)</td>
<td>N/A</td>
<td>0.14***</td>
</tr>
<tr>
<td><strong>Replication Cohort</strong></td>
<td>10</td>
<td>6</td>
<td>10</td>
<td>10</td>
<td>N/A</td>
</tr>
<tr>
<td>Male/female</td>
<td>2/8</td>
<td>3/3</td>
<td>6/4</td>
<td>4/6</td>
<td>0.39*</td>
</tr>
<tr>
<td>Age, mean ± SD, y</td>
<td>45.9 ± 16.1</td>
<td>31.7 ± 10.5</td>
<td>45.8 ± 12.2</td>
<td>41.5 ± 14.0</td>
<td>0.19**</td>
</tr>
<tr>
<td>Disease duration, median (range), y</td>
<td>8.1 (0.2–22.3)</td>
<td>4.9 (0.4–14.1)</td>
<td>0.9 (0.2–33.2)</td>
<td>N/A</td>
<td>0.41***</td>
</tr>
</tbody>
</table>

AU, HLA-B27–associated anterior uveitis; HC, healthy control; N/A, not applicable.
* Fisher’s exact test.
** ANOVA.
*** Kruskal-Wallis.
under the ROC curve revealed that these miRNAs displayed relatively good specificity and sensitivity (Supplementary Table S2).

We observed no statistically significant correlations between the levels of selected miRNAs and age, sex, lymphocyte and leukocyte count, development of ocular complications, or need for treatment with systemic medication. Interestingly, we did find an inverse correlation between disease duration and the serum levels of U6 snRNA, which was seemingly driven by AU patients (Supplementary Fig. S5).

**Uveitis-Associated miRNA Cluster Targets Inflammatory and Ocular Biology Pathways**

To aid in the understanding of the widespread downstream effects of the identified miRNAs in NIU, we narrowed down relevant disease pathways by selecting genes targeted by at least two of the uveitis-associated miRNAs by using miRTarLink.35 Together, six miRNAs shared 37 gene targets (Fig. 3A). Pathway enrichment analysis (see Materials and Methods) for these overlapping gene targets revealed significant (FDR-corrected \( P < 0.05 \)) enrichment for inflammatory and ocular biology pathways (Fig. 3B).

**The NIU-Specific miRNA Cluster Is Associated With Altered Frequencies of CD16\(^+\) Leukocytes**

The expression levels of the seven miRNAs were strongly correlated with each other and therefore further considered as a single uveitis-associated miRNA cluster (Fig. 3C; Supplementary Fig. S6). We hypothesized that the uveitis-associated miRNA cluster can reflect specific changes in leukocyte populations.44–47 To investigate this, we first used noncoding RNA array data (825 overlapping miRNAs) across 113 samples of nine primary leukocyte populations—covering most cell populations of the immune system. Consistent with literature, the derived miRNA-ome was highly cell-type specific (Fig. 4A). Principle component analysis clearly distinguished a lymphoid cluster (T cells, B cells, natural killer [NK] cells) and two myeloid clusters (Fig. 4B). Among the major miRNAs contributing to the clustering of these populations were miR-223-3p and miR-29a-3p (Fig. 4B; Supplementary Fig. S7). The expression of the other uveitis-associated miRNAs also varied considerably between the populations (Supplementary Fig. S8). Using correlation, we mapped the uveitis-associated miRNAs to remote clusters of expression across the leukocyte populations (Supplementary Fig. S9). To verify whether the distinguished expression of the miR-29a-3p and miR-223-3p across the leukocyte subsets reflects meaningful downstream biological differences, we mined mass spectrometry–based proteomic data of the investigated cell subsets (\( n = 162 \)) for the expression of validated target genes (Supplementary Fig. S10; Supplementary Table S5). Unsupervised hierarchical clustering of the miRNA-target proteome of miR-29a-3p and miR-223-3p clearly discerned the myeloid and lymphoid cell subsets (Fig. 4C).

Finally, we wished to explore whether the miRNA cluster tagged changes in specific leukocyte subsets in uveitis patients.
To this aim, we exploited available flow cytometry data from 30 NIU patients and 15 controls from this study (see Supplementary Methods; Supplementary Table S2). Unbiased computational mining of the flow cytometry data by Citrus identified two cell clusters that displayed significantly changed cell abundance according to the expression of the miRNA signature. These included a cluster of lymphocytes (cluster A; Figs. 4D, 4E, and Supplementary Fig. S11) and a cluster of populations characterized by high CD16 expression, dim expression of lineage marker (lin^dim) and CD11c, and low levels of HLA-DR and the monocyte marker CD14 (cluster B1-3, Supplementary Fig. S11), reminiscent of CD16^+CD56^dim NK cells. This CD16^+ cluster also contained populations with low but distinguished expression of CD141 and CD303, most likely residual granulocyte populations (cluster B2 and B3; Figs. 4D, 4E). These observations link a disease-associated circulating miRNA cluster with marked changes in the leukocyte repertoire in the blood of patients with NIU.

**DISCUSSION**

Using a high dimensional and multilevel approach we identified and independently validated the presence of a
uveitis-specific miRNA cluster. This uveitis cluster comprised six miRNAs and a small nuclear RNA that suggest the involvement of several inflammatory signaling cascades (PI3K/Akt, MAPK, FOXO, and VEGF signaling) involved in several eye diseases. In addition, our work showed improved power to validate (70% of selected miRNAs were replicated) as well as to understand the potential role of circulating miRNAs in pathologic conditions without the necessity to have large cohorts.

NIU denotes a collective of clinically heterogeneous intraocular inflammatory diseases that share immune characteristics with—and commonly form an underappreciated feature of—systemic (auto)inflammatory conditions.\textsuperscript{10,51–53} This led us to deliberately study two cohorts (discovery and replication cohort) of treatment-free patients with eye-restricted and active disease. This allowed us to better address the impact of intraocular inflammation on miRNAs in the circulation. To the best of our knowledge, this resulted in the first miRNA investigation of NIU patients without underlying (or potentially confounding) systemic disease.\textsuperscript{54–56}

The main aim of the study was to explore the circulating miRNA profile of NIU to better understand its enigmatic etiology and lay the groundwork for emerging noncoding RNA–based therapeutics to reverse NIU.\textsuperscript{57} Yet, a major obstacle for bringing small RNAs into consideration for therapeutic targeting is the notoriously low concordance and reproducibility between available technologies for detecting differential expression, which consequently results in conflicting reports on candidate identification. Although recommendations for quality control\textsuperscript{58} have improved reproducibility, we also invested additional efforts in assembling an independent replication cohort to be able to identify a robust set of uveitis-associated miRNAs.

The quest for understanding the downstream effects of serum miRNA perturbations is a highly ambiguous one. Individual miRNAs regulate numerous genes, while a single gene can be regulated by a panel of miRNAs targeting the same pathways.\textsuperscript{17,59} Yet, most biological processes are tuned by the concerted action of multiple miRNAs targeting the same pathways.\textsuperscript{18,19,60} Given the close correlation of miRNA levels, as well as overlapping predicted and experimentally validated pathways, it is tempting to speculate that the identified miRNA signature acts as a pathologic ensemble driving—or responding to—ocular inflammation. Functional experiments with appropriate multi-miRNA knockout and conditional (over)expression models will be necessary to pinpoint the functional consequences of our observations.

Several recent key studies highlight the importance of our observations. miR-223-3p is upregulated in animal models of uveitis and is able to drive inflammation via T cells and myeloid dendritic cells, two cell types that are implicated in the biology of uveitis.\textsuperscript{10,61–65} Myeloid-derived mir-223 is critical to innate immunity during gut inflammation, and skewed serum levels of this miRNA may hint toward a dysbiotic microbiome.\textsuperscript{66–68} This is particularly interesting, since commensal microbiota can trigger autoimmune uveitis in mice.\textsuperscript{69} Consequently, miR-223-
3p has been suggested as a good candidate for miRNA targeting in the treatment of inflammatory diseases such as NIU. 70

We explored if the levels of the uveitis-associated signature were correlated with changes in specific blood cell populations of these same patients. We focused on leukocytes because previous studies have highlighted a predominant function of leukocytes in uveitis.10 We realize that the flow cytometry panels used here may lack the resolution needed for an in-depth analysis of all leukocyte populations in blood (outside the scope of this study), yet we were able to highlight several interesting changes; we identified a decreased frequency of a cell population distinguished by high CD16 expression. As based on other cell surface markers (CD11c+ HLA-DR CD14 low), this cluster most likely represents the

![Figure 3](https://example.com/figure3.png)

**Figure 3.** miRNA-target analysis of the validated serum microRNAs in noninfectious uveitis. (A) miRNA-target network of established overlapping miRNA targets of the uveitis-associated miRNAs. miRNAs are depicted in brown boxes and the mRNA targets are depicted in blue (targeted by two miRNAs) or orange (targeted by three miRNAs) boxes. Lines indicate level of evidence: strong (green), weak (blue), or predicted (yellow). Figure generated with MirTargetLink. (B) Heatmap of unscaled FDR-corrected P values for miRNA-target pathways related to inflammation and eye biology. Pathway analysis (ToppGene suite) was performed on miRNA targets that were shared between at least two miRNAs. Clustering was performed by using Euclidean distance and Ward linkage. (C) Heatmap of unsupervised hierarchical clustering of the correlation of expression (TaqMan RT-qPCR for the discovery and replication cohorts combined) for validated serum cluster. Heatmap colors represent Spearman's ρ (calculated on ddCT). ERK, extracellular regulated kinase; FoxO, Forkhead box O; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; ROS, reactive oxygen species; VEGF, vascular endothelial growth factor.
Cytotoxic CD16^+ CD56dim NK cells, a cell type that plays a critical role in the first line of defense against infected, cancerous, and autoreactive cells. Also, this is the major NK subset in blood that typically expresses killer immunoglobulin-like receptors, a receptor that is implicated in the biology of NIU. \textsuperscript{48,71}

It is tempting to speculate that the increased frequency of the lymphocyte cluster represents CD4^+ T cells. We observed...
that the uveitis-associated miR-140-5p and miR-29a-3p are typically more highly expressed in lymphocyte populations, including CD4+ T cells. miR-140-5p, which had the highest discriminative power between uveitis patients and controls, is aberrantly expressed and implicated in pathogenic T-cell function in multiple sclerosis,27–29,32 a disease linked to IL17. It is important to emphasize, however, that the functions of miR-140-5p (and miR-29a-3p) most likely expand beyond T-cell function. For example, we also noted associated pathways relevant for ocular biology, including VEGF signaling.33,59

These ocular biology pathways may attempt to control damage to ocular tissues. U6 snRNA is a small nuclear RNA (snRNA) that is normally localized in the nucleus, but blood microvesicles or exosomes—which vastly increase in number in the circulation during inflammation—are also particularly enriched for U6 nuclear RNA.83,84 Curiously, U6 snRNA is widely used for normalization of miRNA expression studies.85,86 While we here showed that the levels of this miRNA are robustly upregulated in the serum of uveitis patients, this is also increasingly reported for other conditions.87–90

Our results have to be interpreted with the following study limitations in mind. First, although we believe that our stringent selection criteria contributed to the robust identification and replication of uveitis-associated miRNAs, it consequently also limited sample size and power to detect more subtle differences. It seems reasonable to speculate that this may have prevented the detection of a relation between the miRNA levels and heterogeneous clinical end-points, and hampered the validation of differences between uveitis subtypes. Overall, we would like to emphasize that the study of miRNAs in serum is by no means exhaustive, and recapitulate that the identified miRNAs most likely function in clusters of functionally related mediators that orchestrate molecular route function into complex behavior of the immune system in uveitis. As such, the here identified miRNA signature serves as an important starting point to further functionally dissect the epigenetic regulation by these miRNAs and their interaction within the cellular immune system of patients with NIU.

In conclusion, our data demonstrate systemic changes in epigenetic regulation that link serum miRNA levels to changes in leukocyte populations underlying inflammatory eye disease.

Acknowledgments

The authors thank Eleni Chouri and Jorje Mertens for analytical support and useful discussions. Supported by unrestricted grants from Dr. FP Fischer-Stichting and LSBS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclosure: F.H. Verhagen, None; C.P.J. Bekker, None; M. Rossato, None; S. Hiddingh, None; L. de Vries, None; A. Devaprasad, None; A. Pandit, None; J. Ossewaarde-van Norel, None; N. ten Dam, None; M.C.A. Moret-Pot, None; S.M. Imhof, None; J.H. de Boer, None; T.R.D.J. Radstake, None; J.J.W. Kuiper, None

References


Discovery of a Uveitis Associated MicroRNA Cluster


Chen P, Tucker W, Hannes S, et al. Levels of blood CD1c+ mDC1 and CD1chi mDC1 subpopulation reflect disease...


